Chongqing Lummy Pharmaceutical (300006) - Total Assets
Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) holds total assets worth CN¥2.76 Billion CNY (≈ $404.21 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Chongqing Lummy Pharmaceutical's book value for net asset value and shareholders' equity analysis.
Chongqing Lummy Pharmaceutical - Total Assets Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's total assets have evolved over time, based on quarterly financial data.
Chongqing Lummy Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Chongqing Lummy Pharmaceutical's total assets of CN¥2.76 Billion consist of 62.0% current assets and 38.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 37.5% |
| Accounts Receivable | CN¥453.42 Million | 15.9% |
| Inventory | CN¥201.70 Million | 7.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥217.27 Million | 7.6% |
| Goodwill | CN¥44.95 Million | 1.6% |
Asset Composition Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Chongqing Lummy Pharmaceutical.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chongqing Lummy Pharmaceutical's current assets represent 62.0% of total assets in 2024, a decrease from 64.5% in 2006.
- Cash Position: Cash and equivalents constituted 37.5% of total assets in 2024, up from 6.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, unchanged from 8.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 15.9% of total assets.
Chongqing Lummy Pharmaceutical Competitors by Total Assets
Key competitors of Chongqing Lummy Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥1.60 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
Chongqing Lummy Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.04 | 2.35 | 1.00 |
| Quick Ratio | 1.83 | 2.11 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥852.78 Million | CN¥1.06 Billion | CN¥-4.58 Million |
Chongqing Lummy Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Chongqing Lummy Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.93 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | CN¥2.86 Billion |
| Market Capitalization | $987.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chongqing Lummy Pharmaceutical's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Chongqing Lummy Pharmaceutical's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual total assets of Chongqing Lummy Pharmaceutical from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.86 Billion ≈ $417.89 Million |
-1.21% |
| 2023-12-31 | CN¥2.89 Billion ≈ $423.03 Million |
-5.37% |
| 2022-12-31 | CN¥3.05 Billion ≈ $447.04 Million |
+4.38% |
| 2021-12-31 | CN¥2.93 Billion ≈ $428.28 Million |
-7.02% |
| 2020-12-31 | CN¥3.15 Billion ≈ $460.62 Million |
-10.10% |
| 2019-12-31 | CN¥3.50 Billion ≈ $512.37 Million |
+11.48% |
| 2018-12-31 | CN¥3.14 Billion ≈ $459.59 Million |
+14.61% |
| 2017-12-31 | CN¥2.74 Billion ≈ $401.00 Million |
+10.32% |
| 2016-12-31 | CN¥2.48 Billion ≈ $363.50 Million |
-19.94% |
| 2015-12-31 | CN¥3.10 Billion ≈ $454.03 Million |
+38.28% |
| 2014-12-31 | CN¥2.24 Billion ≈ $328.35 Million |
+2.83% |
| 2013-12-31 | CN¥2.18 Billion ≈ $319.31 Million |
+53.27% |
| 2012-12-31 | CN¥1.42 Billion ≈ $208.34 Million |
+31.71% |
| 2011-12-31 | CN¥1.08 Billion ≈ $158.18 Million |
+22.28% |
| 2010-12-31 | CN¥884.01 Million ≈ $129.36 Million |
+35.25% |
| 2009-12-31 | CN¥653.63 Million ≈ $95.65 Million |
+143.38% |
| 2008-12-31 | CN¥268.56 Million ≈ $39.30 Million |
+25.09% |
| 2007-12-31 | CN¥214.69 Million ≈ $31.42 Million |
+71.61% |
| 2006-12-31 | CN¥125.10 Million ≈ $18.31 Million |
-- |
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more